Iambic set the price of its IPO at $16 per share for 9,375,000 newly issued shares on 14 October 2026. Its official release puts expected gross proceeds at $150 million, while the final SEC-filed prospectus estimates $135 million net after underwriting discounts, commissions and estimated offering expenses.
This is a dated financing explainer checked on October 18—not an announcement that bidding has opened today. The company’s earlier release expected trading on October 15 and closing on October 16. Completion has not been independently verified in this check.
Iambic IPO: verified financing terms
| Item | Verified information | Primary evidence |
|---|---|---|
| Issuer / venue | Iambic Therapeutics, Inc.; Nasdaq Global Select Market, IAM | Source |
| Pricing date / price | 14 October 2026 / $16 per share | Source |
| Base offer / fresh versus resale | 9,375,000 shares; all base shares offered by Iambic, not selling holders | Source |
| Gross / estimated net | $150 million gross / $135 million net estimate before any full option exercise | Source |
| Underwriter option | Up to 1,406,250 additional shares within 30 days | Source |
| Trading / closing schedule | Expected 15 October / 16 October 2026, respectively; closing subject to customary conditions | Source |
| Lot, minimum application, par value, transfer agent | Not verified in this report; Indian retail/NII minimums are not carried over | Source |
| Intended use of funds | Clinical development of IAM1363, IAM217 and IAM-C1; platform investment; working capital/general corporate purposes; possible investments or acquisitions | Source |
A $150 million headline is not the net budget
The base-offer arithmetic is 9,375,000 × $16 = $150 million. Subtracting the prospectus’s $135 million net estimate gives a $15 million difference for underwriting and estimated offering costs combined. It is not a measure of revenue, operating profit or money already deployed. The optional additional shares are separate; an option grant does not mean it has been exercised.
Funding development is not a clinical result
The prospectus lists planned clinical-development work and investment in the company’s technology platform. It also allows a portion for possible acquisitions or investments, but says there were no agreements or commitments for material acquisitions or investments at that time. These are intended uses and flexibility, not completed spending decisions.
Iambic describes itself as a clinical-stage life-sciences and technology company. AI-assisted discovery and a funded trial plan do not establish regulatory approval, a successful trial or future product sales. Readers should keep the financing terms, the actual closing record and later scientific/regulatory milestones separate. No claim about post-IPO share performance is made here. More CapKet IPO reporting.
Recorded source observation: (UTC). This is a source-check timestamp, not a market quote or a new article update.